Aeglea BioTherapeutics is in the process of developing an enzyme replacement therapy for patients with CBS Deficiency Homocystinuria.
For the most up to date news on their enzyme replacement, please visit their website: Click here
October 10, 2018
Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting
Positive Preclinical Efficacy Data on its AEB4104 Homocystinuria Therapeutic Program